0.59
+2.61%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Orthocell
Its shares trade on ASX under the ticker OCC.AX. It has been listed since 12 August 2014. In the fiscal year to 30 June 2026, it reported revenue of A$11.4m and a net loss of A$13.9m. At that date it held total assets of A$54.8m and shareholders' equity of A$34.4m.
Orthocell Ltd. engages in the development and commercialization of cell therapies and related technologies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes CelGro, Striate+, Remplir, and SmrtGraft. CelGro is a collagen medical device that facilitates tissue reconstruction and healing in a variety of dental and orthopedic reconstructive applications. CelGro is manufactured using a SMRT manufacturing process to preserve the natural collagen structure. Striate+ is used for dental GBR applications. Remplir is for peripheral nerve reconstruction. SmrtGraft is for tendon repair. Its other major products are autologous cell therapy, which focuses on regenerating damaged tendon and cartilage tissue. The company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Aug 2014
- Website
- orthocell.com.au ↗
Leadership
Pay as last reported
- Mr. John Van Der WielenIndependent Non-Executive Chairman of the Board
- Mr. Jim PiperChief Financial Officer
- Prof. Ming Hao ZhengChief Scientific Officer
- Mr. Paul AndersonManaging Director, Executive Director, since 2006
- Mr. Peter WebseCompany Secretary
- Dr. Ravi ThadhaniLead Independent Director
- Mr. Michael McnultyNon-Executive Director
- Prof. Fiona WoodIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Orthocell Ltd. develops and commercializes cell therapies and related technologies.
- The company's products include CelGro, Striate+, Remplir, and SmrtGraft for tissue repair applications.
- Orthocell focuses on regenerating mobility for patients through products for bone and soft tissue injuries.
Weaknesses
- The company's website is untrusted as per the source description.
- Orthocell's product portfolio is limited to specific medical applications without broader diversification.
- The company's focus on autologous cell therapy may limit scalability compared to off-the-shelf products.
Opportunities
- Orthocell is developing tendon cell therapy in the United States, expanding its market reach.
- The company's SMRT manufacturing process preserves natural collagen structure, offering a unique technological advantage.
- Growing demand for regenerative medicine solutions presents potential market expansion opportunities.
Threats
- The untrusted nature of the source description may affect the reliability of company information.
- Competition in the biotechnology sector could challenge Orthocell's market position.
- Regulatory hurdles in developing and commercializing cell therapies may delay product launches.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.